Dong-A Pharmaceutical Co., Ltd.

As of June 30, 2026, Dong-A Pharmaceutical Co., Ltd. carries a market capitalization of 521.94B, placing it among publicly traded companies globally. Its enterprise value stands at 991.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Dong-A Pharmaceutical Co., Ltd.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Dong-A Pharmaceutical Co., Ltd. has 6.44M shares outstanding.

As of June 30, 2026, Dong-A Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 6.35. The price-to-sales ratio is 0.36, and the price-to-book ratio stands at 0.44.

As of June 30, 2026, Dong-A Pharmaceutical Co., Ltd. trades at an EV/EBITDA multiple of 9.23 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.65 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.23 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 991.42B versus a market cap of 521.94B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Dong-A Pharmaceutical Co., Ltd. maintains a current ratio of 0.82, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Dong-A Pharmaceutical Co., Ltd. posted a return on equity (ROE) of 7.44, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 4.00, measuring how efficiently the asset base is converted into earnings. The company generates approximately 18.51B in revenue per employee across its workforce of 82.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 5.24 indicates how many times Dong-A Pharmaceutical Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Dong-A Pharmaceutical Co., Ltd. recorded an income tax benefit of -348.06M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 84.53B, leaving 85.25B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Dong-A Pharmaceutical Co., Ltd.'s stock has declined approximately 15.53% over the past 52 weeks. The 50-day moving average sits at 92,768.00, while the 200-day moving average is 94,553.11.

Over the twelve months ended June 30, 2026, Dong-A Pharmaceutical Co., Ltd. generated 1.52T in revenue and converted that into 85.25B in net income, yielding earnings per share of 12,723.52. EBITDA reached 107.36B, while operating income came in at 107.36B.

As of June 30, 2026, Dong-A Pharmaceutical Co., Ltd. holds 232.38B in cash and equivalents against 687.36B in total debt, resulting in a net debt position of 385.97B. Total book value stands at 1.19T, with working capital of -131.82B providing operational flexibility.

Dong-A Pharmaceutical Co., Ltd. produced 248.10B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -63.12B in capital expenditures, free cash flow totaled 184.98B - equivalent to 27,731.02 per share.

Over the twelve months ended June 30, 2026, Dong-A Pharmaceutical Co., Ltd. posted a gross margin of 32.00, reflecting its pricing power and cost economics. The operating margin of 7.07 and net profit margin of 5.62 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Dong-A Pharmaceutical Co., Ltd. paid dividends of 675.35 per share. The dividend payout ratio of 5.33 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 34.19, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 20.61, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Dong-A Pharmaceutical Co., Ltd. shareholders.

Dong-A Pharmaceutical Co., Ltd.'s most recent stock split took place on March 11, 2026 with a 100:103 split ratio.

As of June 30, 2026, Dong-A Pharmaceutical Co., Ltd. has an Altman Z-Score of 1.79, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.